Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
CNY 22.9
(-0.82%)
CNY 22.9
(-0.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.24 Billion CNY | 8.18% |
| 2022 | 2.99 Billion CNY | 0.86% |
| 2021 | 2.96 Billion CNY | 4.52% |
| 2020 | 2.84 Billion CNY | -4.89% |
| 2019 | 2.98 Billion CNY | 15.14% |
| 2018 | 2.59 Billion CNY | 28.15% |
| 2017 | 2.02 Billion CNY | 116.25% |
| 2016 | 936.23 Million CNY | 11.68% |
| 2015 | 838.28 Million CNY | 65.3% |
| 2014 | 507.11 Million CNY | 140.73% |
| 2013 | 210.65 Million CNY | 251.2% |
| 2012 | 59.98 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.37 Billion CNY | 4.01% |
| 2024 Q2 | 3.23 Billion CNY | -4.0% |
| 2024 Q3 | 3.08 Billion CNY | -4.58% |
| 2023 Q3 | 3.31 Billion CNY | -5.58% |
| 2023 Q4 | 3.24 Billion CNY | -2.12% |
| 2023 FY | 3.24 Billion CNY | 8.18% |
| 2023 Q1 | 3.1 Billion CNY | 3.75% |
| 2023 Q2 | 3.5 Billion CNY | 12.83% |
| 2022 FY | 2.99 Billion CNY | 0.86% |
| 2022 Q4 | 2.99 Billion CNY | -3.6% |
| 2022 Q3 | 3.1 Billion CNY | -3.49% |
| 2022 Q2 | 3.21 Billion CNY | 5.26% |
| 2022 Q1 | 3.05 Billion CNY | 2.99% |
| 2021 FY | 2.96 Billion CNY | 4.52% |
| 2021 Q3 | 3.04 Billion CNY | -6.12% |
| 2021 Q4 | 2.96 Billion CNY | -2.59% |
| 2021 Q2 | 3.24 Billion CNY | 7.85% |
| 2021 Q1 | 3.01 Billion CNY | 5.98% |
| 2020 FY | 2.84 Billion CNY | -4.89% |
| 2020 Q1 | 2.91 Billion CNY | -2.52% |
| 2020 Q2 | 2.86 Billion CNY | -1.58% |
| 2020 Q3 | 2.86 Billion CNY | -0.02% |
| 2020 Q4 | 2.84 Billion CNY | -0.84% |
| 2019 Q2 | 2.78 Billion CNY | -1.42% |
| 2019 FY | 2.98 Billion CNY | 15.14% |
| 2019 Q4 | 2.98 Billion CNY | 1.05% |
| 2019 Q1 | 2.82 Billion CNY | 9.0% |
| 2019 Q3 | 2.95 Billion CNY | 6.04% |
| 2018 Q1 | 2.06 Billion CNY | 2.17% |
| 2018 Q2 | 2.29 Billion CNY | 11.09% |
| 2018 Q3 | 2.28 Billion CNY | -0.35% |
| 2018 FY | 2.59 Billion CNY | 28.15% |
| 2018 Q4 | 2.59 Billion CNY | 13.3% |
| 2017 Q1 | 1.74 Billion CNY | 86.66% |
| 2017 Q2 | 1.79 Billion CNY | 2.78% |
| 2017 Q3 | 1.96 Billion CNY | 9.37% |
| 2017 Q4 | 2.02 Billion CNY | 3.06% |
| 2017 FY | 2.02 Billion CNY | 116.25% |
| 2016 Q2 | 919.45 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 936.23 Million CNY | -1.14% |
| 2016 Q3 | 947 Million CNY | 3.0% |
| 2016 FY | 936.23 Million CNY | 11.68% |
| 2015 Q4 | 838.28 Million CNY | 0.0% |
| 2015 FY | 838.28 Million CNY | 65.3% |
| 2014 FY | 507.11 Million CNY | 140.73% |
| 2013 FY | 210.65 Million CNY | 251.2% |
| 2012 FY | 59.98 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Lifecome Biochemistry Co.,Ltd. | 1.96 Billion CNY | -64.897% |
| Chengdu Kanghua Biological Products Co., Ltd. | 4.2 Billion CNY | 23.021% |
| NanHua Bio-medicine Co., Ltd | 771.38 Million CNY | -320.057% |
| Porton Pharma Solutions Ltd. | 9.38 Billion CNY | 65.471% |
| Zhejiang Wecome Pharmaceutical Company Limited | 2.04 Billion CNY | -58.32% |
| Guangdong VTR Bio-Tech Co., Ltd. | 3.09 Billion CNY | -4.695% |